TCTMD’s Top 10 Most Popular Stories for April 2017
Conference news, BVS thrombosis, complex PCI, TAVR decisions, and the origins of atherosclerosis were among our most popular topics this month.
Two tales of the challenges faced by the Absorb bioresorbable vascular scaffold (BVS) topped our list for April 2017, followed by a feature story exploring the potential role for palliative care in the TAVR decision-making pathway. Several stories from the American College of Cardiology 2017 Scientific Session in March made their way onto this month’s list, as did two stories from the European Atherosclerosis Society (EAS) 2017 conference that has just wrapped up in Prague. Cardiogenic shock, conscious sedation in TAVR, and same-day discharge after PCI round out this month’s most popular stories.
If you’re craving more great content from April, check out Heart Sounds, our monthly podcast that lets you listen to parts of the interesting interviews conducted for TCTMD in the month gone by.
The CE Mark approval remains in place, but only centers participating in formal registries should be using the bioresorbable device for now.
Rates of definite stent thrombosis were fivefold higher with the newer technology, but some experts are still hoping to see benefits over the long term.
Some say palliative care should be part of the heart team, while others worry it might discourage patients from getting life-saving treatments.
In a blow to interventionalists, the results did not show a benefit of the procedure over medical therapy alone. But hope remains.
The tool could be used to guide early management decisions or to identify ideal patients for clinical trials, researchers say.
Experts at the annual EAS meeting tasked with arguing these two theories ultimately agreed that the answer is not black and white.
STS/ACC TVT Registry data demonstrate the efficacy and safety of the procedure, but mortality remains high overall.
TAVR without general anesthesia should become the norm for transfemoral TAVR, a single-center study suggests. “Buy-in” from the heart team is key.
Data from more than 200 different studies show consistent linear and dose-dependent relationships “unequivocally,” confirming causality, authors say.
Views on what constitutes an “appropriate and safe length of stay” vary, a new survey of interventional cardiologists in the US, Canada, and UK shows.